Objective-The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. We previously reported on this risk association using NAT2 phenotypic categories inferred from NAT2 haplotypes based on 7 single nucleotide polymorphisms (SNPs) in a study in Spain. In a subsequent genome-wide scan, we have identified a single common tag SNP (rs1495741) located in the 3′ end of NAT2 that is also associated with bladder cancer risk. The aim of this report is to evaluate the agreement between the common tag SNP and the 7-SNP NAT2 inferred phenotype.
INTRODUCTION
García-Closas et al. Page 2 Differences in the acetylation activity of the arylamine N-acetyltransferase 2 (NAT2) gene were first discovered in 1950's as modifiers of the neurotoxic effects of the anti-tuberculosis drug isoniazid 1 . Polymorphisms in the NAT2 gene have been extensively studied as modifiers of drug efficacy/toxicity and cancer risk because of its key role of the isoenzyme in the metabolism of arylamine and hydrazine drugs and carcinogens. 2 The underlying genetic basis of differences in NAT2 enzyme activity has been explained by a combination of single nucleotide polymorphisms (SNPs) in the coding region (exon 2) of the NAT2 gene. 3 Extensive effort has been devoted to the characterization of the functional effects of these SNPs and their haplotypes on NAT2 activity. [3] [4] [5] [6] [7] These observations have established a solid foundation for inferring the NAT2 rapid, intermediate and slow phenotypic classification based on the co-dominant expression of rapid and slow acetylator NAT2 haplotypes. 4, 5 Many epidemiological studies of cancer risk have used genotyping to infer NAT2 phenotypic classification, since directly measuring NAT2 activity in humans would require complex and cumbersome phenotypic assays, such as measuring urinary metabolites after caffeine administration. 8 A panel of 7 NAT2 SNPs has been recommended to accurately assign NAT2 haplotypes and inferred phenotype in populations of European background. 9 These include four SNPs known to reduce NAT2 activity by different mechanisms (rs1801279 (R64Q), rs1801280 (I114T), rs1799930 (R197Q) and rs1799931 (G286E)), and three SNPs that do not cause changes in enzyme activity (rs1041983 (Y94Y), rs1799929 (L161L) and rs1208 (K268R)), 3, [5] [6] [7] but are needed to assign the NAT2 haplotypes and inferred phenotypic categories with high accuracy. 9, 10 One of the most consistent associations with cancer risk has been for an increased risk of urothelial cell carcinoma of the bladder in NAT2 slow compared to rapid/intermediate acetylators. 11, 12 Specifically, meta-analyses have shown that the NAT2 slow acetylation phenotype (mostly inferred from NAT2 haplotypes based on 3 to 7 NAT2 SNPs) is associated with an increased bladder cancer risk in populations of European background: summary odds ratio (OR) of 1.35 (95% CI 1.22-1.55) P=2×10 −8 , based on 4,403 cases and similar numbers of controls from 24 studies. 12 In addition, the NAT2 association might be limited to cigarette smokers, which is consistent with the role of NAT2 in detoxification of aromatic amines in tobacco smoke, known bladder carcinogens. 11, 12 In this report, we evaluate the agreement between rs1495741, a tag SNP ~14kb 3′ of NAT2 discovered in a bladder cancer genome-wide association study (GWAS) 13 , with the NAT2 inferred phenotype 11 .
MATERIALS AND METHODS

Spanish Bladder Cancer Study (SBCS)
The Spanish Bladder Cancer Study is a hospital-based case-control study conducted in 18 hospitals from five different regions in Spain. 11 
Cryopreserved human hepatocytes
Genotyping
Cryopreserved human hepatocytes were received from Celsis In Vitro Technologies (Baltimore, MD) and stored in liquid nitrogen until use (see http://www.celsis.com/ivt/characterization-tables/ for details of the source of cells). Hepatocytes were thawed, centrifuged according to manufacturer's instructions and as described previously 15 , and pelleted cells were washed in 1X phosphate buffered saline.
Seven NAT2 SNPs haplotypes, and inferred phenotypic classification were determined as previously described (http://www.louisville.edu/medschool/pharmacology/NAT.html). 11, 16 The seven SNPs included four SNPs known to reduce NAT2 activity by different mechanisms (rs1801279 (R64Q), rs1801280 (I114T), rs1799930 (R197Q) and rs1799931 (G286E), and three SNPs that do not cause changes in enzyme activity (rs1041983 (Y94Y), rs1799929 (L161L) and rs1208 (K268R) but are needed to assign the NAT2 haplotypes and inferred phenotypic categories with high accuracy. A description and methods for each specific genotype assay used in SBCS samples can be found at http://snp500cancer.nci.nih.gov/. Individuals possessing two of the NAT2 alleles associated with rapid acetylation activity (NAT2*4, NAT2*11A, NAT2*12A, NAT2*12B, NAT2*12C, NAT2*13) were classified as rapid acetylators; individuals possessing one of these alleles and one allele associated with slow acetylation (NAT2*5, NAT2*6, NAT2*7, and NAT2*14) were classified as intermediate acetylators, and those individuals that possessed two slow acetylation alleles were classified as slow acetylators. SNP rs1495741 was genotyped on the Illumina Infinium®1M array for the SBCS and the Illumina Infinium®610K array for the NEBCS (ME,VT)) as described (Rothman N, Garcia-Closas M et al., in prep).
Genomic DNA from hepatocytes was isolated from pelleted cells prepared as described above using the QIAamp DNA Mini Kit (Qiagen) according to manufacturer's instructions. NAT2 SNPs, haplotypes and deduced phenotypic classification were inferred as described. 4, 11, 16 rs1495741 was determined by TaqMan assay (http://snp500cancer.nci.nih.gov/
NAT2 activity assays in cryopreserved human hepatocytes
Hepatocytes were lysed in 20 mM sodium phosphate (pH 7.4), 1 mM EDTA, 1 mM dithiothreitol, 100 μM phenylmethanesulfonyl fluoride, and 1 μg/ml aprotin and 1 μM pepstatin A by three rounds of freeze (−70°C)/thawing (37°C). Lysates were centrifuged at 15,000 × g for 20 min and the resulting supernatant assayed for the level of NAT2 activity using the NAT2-selective substrate sulfamethazine (SMZ) as described previously 17 . Briefly, reactions containing lysates (< 2 mg protein/ml which translates into < 0.2 mg protein/reaction), 300 μM SMZ, and 1 mM acetyl coenzyme A were incubated at 37°C for 10 min, ensuring that there was linearity over the reaction period. Reactions were terminated by the addition of 1/10 volume 1 M acetic acid. The reaction tubes were centrifuged to precipitate protein and supernatant was injected onto a Lichrospher 100 RP-18 (125 mm × 4 mm; 5 μm) reverse phase column. Reactants and products were separated by high performance liquid chromatography (HPLC) (Beckman, Fullerton, CA). N-acetyl-SMZ was quantitated by absorbance at 260 nm. Variability per lysate was assessed by conducting reactions in triplicate.
Statistical methods
We constructed 3×3 contingency tables to visualize the agreement between the three rs1495741 genotypes and the three 7-SNP NAT2 inferred phenotype categories. We also estimated sensitivity and specificity as measures of agreement between rs1495741 and the 7-SNP NAT2 inferred phenotype, using the latter as the gold standard and after combining the AG/GG genotypes and the intermediate/rapid NAT2 phenotype categories. We estimated odds ratios (OR) and 95% confidence intervals (CI) from logistic regression models to test for associations between bladder cancer risk and NAT2 genotypes, haplotypes and phenotypes, as well as interactions with cigarette smoking, as previously described 11 .
NAT2 activity according to the rs1495741 genotype was assessed graphically and differences in mean activity by genotype categories were analyzed using one-way analysis of variance (ANOVA). We then fit a linear regression of NAT2 activity against the rs1495741 genotype (coded as an ordered variable with values 0,1,2 for AA, AG and GG genotypes, respectively) to test for a linear dose-response between the two variables.
RESULTS AND DISCUSSION
García-Closas et al. Page 4 In a case-control study of urinary bladder in the Spanish Bladder Cancer Study (SBCS), we inferred the NAT2 acetylator phenotype based on 7 SNPs in exon 2 of NAT2 (7-SNP inferred phenotype). 11 Samples from 2,174 subjects (1,097 cases and 1,077 controls) in this study were also genotyped for a set of one million SNPs (Illumina Infinium® 1M array), as part of a bladder cancer GWAS 13 . This study indentified a strong association for bladder cancer risk for rs1495741, shown in Table 1 : per-allele OR (95%CI)= 1.34 (1.15-1.55); P=1.40 × 10 −4 . This common SNP, located approximately 14Kb in the 3′ end of the NAT2 gene has major allele A and minor allele G (frequency of 0.24 in controls). rs1495741 is located within a large LD block including the 7 previously identified SNPs (S_Figure 1 http://links.lww.com/FPC/A193). Although rs1495741 was highly correlated with NAT2 haplotypes derived from the 7 SNPs, it only showed a modest pairwise correlation with the individual 7 SNPs, four pairs of which were highly correlated (r 2 ≥0.85; S_Table 1 http://links.lww.com/FPC/A194).
Relative risk estimates for the association with bladder cancer in the SBCS were very similar when we used data for the NAT2 7-SNP inferred phenotype 11 and or the rs1495741 genotypes 13 (Table 2 ). These risk estimates were also similar to those previously reported in large meta-analyses, which included SBCS data. 11, 12 Haplotype analyses based on the 8 SNPs (rs1495741 and the 7 NAT2 SNPs) identified one rapid NAT2 allele (NAT2*4), five slow NAT2 alleles (NAT2*5B, *6A, *7B, *5C, 5A, from the most to the least common), and a new haplotype that was NAT2*4 with the A allele of rs1495741 (S_Table 2 http://links.lww.com/FPC/A195). All of the acetylator haplotypes previously recognized as slow (NAT2*5C, *5A, *5B, *7B, *6A) shared the A allele of rs1495741, whereas the rapid haplotype NAT2*4 occurred both with the G allele (0.227 of controls) and, less frequently, with the A allele (0.010 of controls).
As expected by the consistency of risk associations for the NAT2 7-SNP inferred phenotype 11 and rs1495741 identified in the GWAS 13 , the two variables showed strong agreement in samples from the SBCS ( To evaluate the relationship between the NAT2 tag SNP and NAT2 hepatic activity, we determined the rs1495741 genotypes and NAT2 catalytic activity in crypopreserved hepatocytes from 154 individuals of European background. The distribution of NAT2 activity measurements in hepatocytes was strongly associated with the NAT2 7-SNP inferred phenotypes ( Figure 1 , Panel A), as previously reported 17 , and with the rs1495741 genotypes ( Figure 1, Panel B) . The NAT2 activity measurements are tighter for the three NAT2 7-SNP inferred phenotype categories than for the three rs1495741 genotype categories, which is consistent with the slight misclassification we observed between these two variables in the SBCS and NEBCS (ME,VT). rs1495741 genotypes showed similar levels of NAT2 catalytic activity in cryopreserved hepatocytes from nine individuals with the homozygous NAT2*4/ *4 rapid acetylator genotype (data not shown). Additional functional characterization of rs1495741 on NAT2 activity is required to evaluate whether it impinges on NAT2 function independently or through its association with previously identified NAT2 haplotypes. It should also be noted that the NAT2 catalytic activity measured in vitro is not a perfect measure of the true phenotype, and it can be influenced by many extraneous factors such as the source and quality of the hepatocytes and assay conditions, as well as by NAT2 protein instability. These sources of variation could underestimate the relationship between genotypes and NAT2 activity.
CONCLUSION
We have identified a SNP in a bladder cancer GWAS (rs1495741) located ~14kb 3′ of NAT2 that shows almost perfect agreement with the NAT2 phenotype inferred from 7 previously identified SNPs in exon 2 of NAT2. These findings demonstrate the power of GWAS to identify novel markers for disease risk and other phenotypes, including markers of complex functional haplotypes such those known to occur in NAT2. Furthermore, our results indicate that a single SNP, rs1495741 can be analyzed and thus, reduce the complexity of assessing the NAT2 phenotype in epidemiological studies.
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